phibro animal health - PAHC

PAHC

Close Chg Chg %
38.25 -0.94 -2.46%

Closed Market

37.31

-0.94 (2.46%)

Volume: 182.19K

Last Updated:

Sep 8, 2026, 4:00 PM EDT

Company Overview: phibro animal health - PAHC

PAHC Key Data

Open

$37.92

Day Range

36.86 - 37.92

52 Week Range

28.25 - 60.08

Market Cap

$1.55B

Shares Outstanding

40.60M

Public Float

20.86M

Beta

0.47

Rev. Per Employee

N/A

P/E Ratio

15.71

EPS

$2.46

Yield

125.49%

Dividend

$0.12

EX-DIVIDEND DATE

Sep 2, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

222.53K

 

PAHC Performance

1 Week
 
-2.46%
 
1 Month
 
8.81%
 
3 Months
 
18.33%
 
1 Year
 
-5.83%
 
5 Years
 
65.09%
 

PAHC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About phibro animal health - PAHC

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment focuses on the development and marketing of medicated feed additives, nutritional specialty products, and vaccines. The Mineral Nutrition segment includes formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment is involved in the manufacture and marketing of specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

PAHC At a Glance

Phibro Animal Health Corp.
Glenpointe Centre East
Teaneck, New Jersey 07666-6712
Phone 1-201-329-7300 Revenue 1.52B
Industry Pharmaceuticals: Major Net Income 99.72M
Sector Health Technology 2026 Sales Growth 17.117%
Fiscal Year-end 06 / 2027 Employees 2,605
View SEC Filings

PAHC Valuation

P/E Current 15.713
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 12.899
Price to Sales Ratio 0.847
Price to Book Ratio 3.304
Price to Cash Flow Ratio 18.65
Enterprise Value to EBITDA 7.897
Enterprise Value to Sales 1.313
Total Debt to Enterprise Value 0.396

PAHC Efficiency

Revenue/Employee 582,761.228
Income Per Employee 38,280.23
Receivables Turnover 6.357
Total Asset Turnover 1.061

PAHC Liquidity

Current Ratio 2.956
Quick Ratio 1.266
Cash Ratio 0.259

PAHC Profitability

Gross Margin 33.607
Operating Margin 13.23
Pretax Margin 9.047
Net Margin 6.569
Return on Assets 6.968
Return on Equity 29.716
Return on Total Capital 8.492
Return on Invested Capital 9.231

PAHC Capital Structure

Total Debt to Total Equity 204.621
Total Debt to Total Capital 67.172
Total Debt to Total Assets 52.541
Long-Term Debt to Equity 195.386
Long-Term Debt to Total Capital 64.141
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Phibro Animal Health - PAHC

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
977.89M 1.02B 1.30B 1.52B
Sales Growth
+3.78% +4.07% +27.37% +17.12%
Cost of Goods Sold (COGS) incl D&A
678.41M 705.19M 905.25M 1.01B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
34.01M 36.18M 45.60M 51.51M
Depreciation
24.32M 26.52M 37.76M 44.63M
Amortization of Intangibles
9.70M 9.66M 7.84M 6.88M
COGS Growth
+3.51% +3.95% +28.37% +11.34%
Gross Income
299.47M 312.49M 390.97M 510.18M
Gross Income Growth
+4.40% +4.35% +25.12% +30.49%
Gross Profit Margin
+30.62% +30.71% +30.16% +33.61%
2023 2024 2025 2026 5-year trend
SG&A Expense
219.50M 250.07M 269.68M 309.33M
Research & Development
24.39M 29.19M 23.73M 24.55M
Other SG&A
195.10M 220.88M 245.96M 284.78M
SGA Growth
+5.86% +13.93% +7.84% +14.70%
Other Operating Expense
- - - -
-
Unusual Expense
(1.74M) (5.40M) 45.42M 50.88M
EBIT after Unusual Expense
81.72M 67.82M 75.86M 149.97M
Non Operating Income/Expense
900.00K (19.39M) (5.25M) (10.63M)
Non-Operating Interest Income
3.35M 4.47M 2.62M 1.99M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
28.55M 37.51M 2.62M 1.99M
Interest Expense Growth
+191.70% +31.41% -93.01% -24.22%
Gross Interest Expense
28.55M 37.51M 2.62M 1.99M
Interest Capitalized
- - - -
-
Pretax Income
54.07M 10.92M 67.99M 137.35M
Pretax Income Growth
-25.24% -79.81% +522.87% +102.00%
Pretax Margin
+5.53% +1.07% +5.25% +9.05%
Income Tax
21.46M 8.50M 19.73M 37.63M
Income Tax - Current - Domestic
11.61M 4.75M 8.01M 6.34M
Income Tax - Current - Foreign
12.75M 15.74M 16.48M 24.06M
Income Tax - Deferred - Domestic
(6.42M) (6.28M) (5.93M) 7.95M
Income Tax - Deferred - Foreign
3.52M (5.72M) 1.18M (725.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
32.61M 2.42M 48.26M 99.72M
Minority Interest Expense
- - - -
-
Net Income
32.61M 2.42M 48.26M 99.72M
Net Income Growth
-33.69% -92.59% +1,897.68% +106.61%
Net Margin Growth
+3.33% +0.24% +3.72% +6.57%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
32.61M 2.42M 48.26M 99.72M
Preferred Dividends
- - - -
-
Net Income Available to Common
32.61M 2.42M 48.26M 99.72M
EPS (Basic)
0.805 0.0596 1.1913 2.4594
EPS (Basic) Growth
-33.70% -92.60% +1,898.83% +106.45%
Basic Shares Outstanding
40.50M 40.50M 40.52M 40.55M
EPS (Diluted)
0.805 0.0596 1.1865 2.4343
EPS (Diluted) Growth
-33.70% -92.60% +1,890.77% +105.17%
Diluted Shares Outstanding
40.50M 40.52M 40.68M 40.96M
EBITDA
113.99M 98.60M 166.89M 252.37M
EBITDA Growth
+1.59% -13.50% +69.27% +51.21%
EBITDA Margin
+11.66% +9.69% +12.88% +16.62%

Snapshot

Average Recommendation HOLD Average Target Price 45.00
Number of Ratings 5 Current Quarters Estimate 0.767
FY Report Date 09 / 2026 Current Year's Estimate 3.501
Last Quarter’s Earnings 0.85 Median PE on CY Estimate N/A
Year Ago Earnings 3.22 Next Fiscal Year Estimate 3.851
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 3 5 5
Mean Estimate 0.77 0.97 3.50 3.85
High Estimates 0.78 1.01 3.53 4.04
Low Estimate 0.75 0.92 3.48 3.68
Coefficient of Variance 1.92 4.79 0.54 3.52

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 3 3 3
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Phibro Animal Health - PAHC

Date Name Shares Transaction Value
Nov 20, 2025 BFI Co. LLC President and CEO; Director 60,240 Conversion of derivative security 0.00
Nov 20, 2025 BFI Co. LLC President and CEO; Director 54,960 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $44.56 per share 2,449,017.60
Nov 20, 2025 BFI Co. LLC President and CEO; Director 49,700 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $43.82 per share 2,177,854.00
Nov 20, 2025 BFI Co. LLC President and CEO; Director 49,680 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $44.28 per share 2,199,830.40

Phibro Animal Health in the News